Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eliciting B cell immunity against infectious diseases using nanovaccines.

Nature nanotechnology - 1 Jan 2021

Singh Ankur

Abstract excerpt

Infectious diseases, including the coronavirus disease 2019 (COVID-19) pandemic that has brought the world to a standstill, are emerging at an unprecedented rate with a substantial impact on public health and global economies. For many life-threatening global infectious diseases, such as human immunodeficiency virus (HIV) infection, malaria and influenza, effective vaccinations are still lacking. There are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antigen Presentation
Share to B-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Communicable Diseases

Share to Lymph Nodes

Share to Microbiota

Share to Nanoparticles

Share to Vaccines

Source

Open in PubMed Open full text

Identifiers

PMID: 33199883
DOI: 10.1038/s41565-020-00790-3
PMCID: PMC7855692

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eliciting B cell immunity against infectious diseases using nanovaccines.PMID 33199883Read ↗

Efficient Nanovaccine Delivery in Cancer ImmunotherapySemantic proximity Read ↗

Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of ProteinsSemantic proximity Read ↗

In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure‐Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive ImmunitySemantic proximity Read ↗

Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine designSemantic proximity Read ↗

Nanocell COVID-19 vaccine elicits iNKT-licensed dendritic cells to produce high affinity antibodies neutralizing Variants of ConcernSemantic proximity Read ↗

DNA origami vaccine (DoriVac) nanoparticles improve both humoral and cellular immune responses to infectious diseasesSemantic proximity Read ↗

Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2Semantic proximity Read ↗

Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2Semantic proximity Read ↗

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriersSemantic proximity Read ↗

Recent Progress on the Versatility of Virus-Like ParticlesSemantic proximity Read ↗

Kinetically activating nanovaccine mimicking multidimensional immunomodulation of natural infection for broad protection against heterologous viruses in animal modelsSemantic proximity Read ↗

Multiscale dynamic immunomodulation by a nanoemulsified Trojan-TLR7/8 adjuvant for robust protection against heterologous pandemic and endemic virusesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.